Its role Owner
Johnson & Johnson is a U.S.-based multinational healthcare company headquartered in New Brunswick, New Jersey. It operates through two primary segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company discovers, develops, manufactures, and markets prescription therapeutics and medical technologies worldwide, with focus areas that include oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolism, and pulmonary hypertension. Janssen Biotech, Inc., and related Janssen entities form part of its pharmaceutical operations.
From a chemicals and manufacturing perspective, Johnson & Johnson’s pharmaceutical business spans small-molecule active pharmaceutical ingredient (API) synthesis, biologics and monoclonal antibody production, and sterile, parenteral, and solid-dose drug product manufacturing. These activities are supported by a global R&D and GMP manufacturing network, alongside extensive external partnerships and licensing arrangements. The company maintains large-scale quality, regulatory, and supply chain capabilities to supply medicines to markets worldwide.
Also known as Janssen Biotech, Inc..
chemXplore tracks 2 projects involving J&J, of which 2 are active.
Closest to start-up first.
Phase 3 GALAXI 2 and 3 Week 144 LTE data report high rates of clinical, corticosteroid‑free and endoscopic remission with two maintenance regimens; 74% remained on treatment at three years.
Phase 3 data show sustained PASI90/PASI100 and IGA 0/1 responses to Week 112, durable itch improvement, and no new safety signals.
Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.
Oral ICOTYDE maintains durable skin clearance through Week 112 and yields high site‑specific clearance rates for scalp, genital, hand/foot and nails.
Two‑year Vibrance‑MG data show maintained MG‑ADL and QMG improvements and steroid reductions in adolescents; HCP survey links fluctuating control to switches to IMAAVY.
Single CARVYKTI infusion produced treatment-free, progression-free remissions at five years in half of early-line relapsed/refractory multiple myeloma patients.
Phase 4 STAR trial: guselkumab improved BASDAI at Week 24, reduced ASDAS‑CRP and MRI sacroiliac inflammation in biologic‑naïve axial PsA; safety profile consistent.
Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.
active all projects
